Philippe Monteyne is a Partner at Aliath Bioventures.
Before joining Aliath, Philippe was Senior Partner at Fund+, an open ended VC fund in Belgium, focusing on long-term equity investments in innovative life sciences companies across Europe. Fund+ made 18 investment and generated very attractive returns.
Philippe held board positions at Mynorix, Aelix, Ona Tx, Novadip, Exevir, Egle Tx and Coave Tx. His track record includes the contribution to very successful exits like Ogeda (€800M with €500M upfront), and Iteos (NASDAQ IPO $1bn+). Philippe was also a board member at BIOASTER (Institute for technological innovation in microbiology), at LEEM (French Pharmaceutical Association) and at the “Fondation Plan Alzheimer France”.
In addition to Aliath, Phillipe will remain as an independent board member at Aelix, a member of the strategic committee at Op2lysis and as part-time professor and course coordinator of Advanced Masters in Biotech & MedTech Ventures (at Solvay Management School).
Dr. Monteyne has a long-established professional experience in pharma, having been VP of R&D France at Sanofi and Head of Global Vaccines at GSK (overseeing the development of Cervarix eg, the cervical cancer vaccine), and Head of Development and CMO at GSK Rare Diseases. Philippe is a fully trained neurologist (M.D), with a PhD in viral immunology from Université Catholique de Louvain, a post-doc in neuroimmunology at Pasteur Institute (Paris) and an Advanced Management Programme from INSEAD.
